Cynthia Herzog

Professor

MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Background: Ifosfamide, an alkylating agent used for treating various cancers, can cause encephalopathy in 10–30% of adults and 8% of children. Methylene blue has been used to treat ifosfamide-induced encephalopathy (IIE). This study aimed to describe our institutional experience with IIE in children and young adults with cancer, including its clinical manifestations, treatment, and outcomes. Methods: We reviewed the clinical records of patients with cancer aged up to 30 years who developed IIE over 10 years. Results: Twenty-four patients (median age: 17.6 years, range: 4–30 years) were included; 54% were male, and 71% had bone/soft tissue sarcomas. Ifosfamide was administered alone or with other drugs (dose range: 1.5–3.3 g/m2/day). Twelve patients developed IIE after short intermittent infusions (1–3 h), and twelve developed it after continuous infusions (12–24 h). IIE occurred at a median cumulative ifosfamide dose of 18 g/m2. Symptoms appeared within hours to five days and resolved within 24–120 h. An altered mental status was present in all except one patient. Twelve patients had grade 3 IIE (severe somnolence, agitation, and confusion), and five had grade 4 IIE (coma and seizures). Twenty patients (83%) received methylene blue, with symptom resolution in nineteen patients (83%). Imaging studies showed nonspecific findings. Ten patients were re-challenged with ifosfamide; five received prophylactic methylene blue treatment, of whom three had recurrence. Conclusions: IIE can occur with both short intermittent and continuous ifosfamide infusions and presents as an altered mental status, seizures, and, rarely, hemiparesis. Symptoms are transient, and methylene blue may help alleviate this neurotoxicity, but it does not completely prevent its recurrence.

Year:

2025

Supplement Table 1: Histologic Make-up of common sarcomas Supplement Table 2: List of common alterations among URS population by frequency Supplement Table 3: Sarcomas experiencing without clinical benefit (e.g. SD for

Year:

2025

Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients with advanced sarcoma. Experimental Design: In this retrospective analysis, investigational treatment characteristics and longitudinal survival outcomes were analyzed in patients with biopsy-confirmed sarcoma enrolled in early-phase trials at MD Anderson Cancer Center from May 2006 to July 2021. Results: Five hundred eighty-seven patients were included [405 soft tissue, 122 bone, 60 gastrointestinal stromal tumor (GIST); median of three prior lines of therapy]. Most common subtypes were leiomyosarcoma (17.2%), liposarcoma (14.0%), and GIST (10.2%). Molecular testing was available for 511 patients (87.1%); 221 patients (37.6%) were treated in matched trials. Overall response rate was 13.1% matched compared with 4.9% in unmatched ( P P P P Conclusions: Enrollment in biomarker-matched early-phase trials is associated with improved outcomes in heavily pretreated patients with metastatic sarcoma. Molecular testing of tumors from patients with advanced sarcoma and enrollment in matched trials is a reasonable therapeutic strategy.

Year:

2024

Collaborators (23)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christina Lynn Roland

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Neeta Somaiah

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard Gorlick

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Aung Naing

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Vivek Subbiah

Professor of Medicine and of Pediatrics

Stanford University

UNITED STATES
View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shreyaskumar Patel

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Douglas J. Harrison

-

UNITED STATES
View details

Justin Moyers

-

UNITED STATES
View details

Anthony P. Conley

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sarina Piha-Paul

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Siqing Fu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J Andrew Livingston

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

VINOD RAVI

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Valerae Lewis

Professor and Chair

MD Anderson Cancer Center

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wei-Lien Wang

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ravin Ratan

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shubham Pant

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details